Analyst Price Targets — KRYS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 12:42 pm | — | Jefferies | $474.00 | $358.52 | TheFly | Krystal Biotech price target raised to $474 from $399 at Jefferies |
| June 16, 2026 1:01 pm | Joseph Pantginis | H.C. Wainwright | $361.00 | $323.00 | TheFly | Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright |
| May 5, 2026 12:11 pm | — | Evercore ISI | $300.00 | $294.07 | TheFly | Krystal Biotech price target raised to $300 from $295 at Evercore ISI |
| February 18, 2026 12:56 pm | Geulah Livshits | Chardan Capital | $323.00 | $282.65 | TheFly | Krystal Biotech price target raised to $323 from $220 at Chardan |
| February 17, 2026 6:26 pm | Roger Song | Jefferies | $371.00 | $291.10 | TheFly | Krystal Biotech price target raised to $371 from $310 at Jefferies |
| January 30, 2026 12:31 pm | — | Goldman Sachs | $327.00 | $279.34 | TheFly | Krystal Biotech price target raised to $327 from $206 at Goldman Sachs |
| January 9, 2026 11:08 am | — | H.C. Wainwright | $310.00 | $248.91 | TheFly | Krystal Biotech price target raised to $310 from $240 at H.C. Wainwright |
| October 17, 2025 10:44 am | Debjit Chattopadhyay | Guggenheim | $224.00 | $188.33 | TheFly | Krystal Biotech price target raised to $224 from $189 at Guggenheim |
| August 22, 2025 12:03 pm | — | Chardan Capital | $216.00 | $150.49 | TheFly | Krystal Biotech price target lowered to $216 from $219 at Chardan |
| September 11, 2024 6:53 am | Dae Gon Ha | Stifel Nicolaus | $220.00 | $185.00 | TheFly | Krystal Biotech price target raised to $220 from $204 at Stifel |
Latest News for KRYS
The sky is the limit for these companies.
Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KRYS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.